CD200 genotype is associated with clinical outcome of patients with multiple myeloma

被引：1

作者：

Gonzalez-Montes, Yolanda ^{[1
]}

Osca-Gelis, Gemma ^{[2
,3
,4
]}

Rodriguez-Romanos, Rocio ^{[1
]}

Villavicencio, Alicia ^{[1
]}

Gonzalez-Bartulos, Marta ^{[1
]}

Llopis, Francesca ^{[1
]}

Clapes, Victoria ^{[5
]}

Oriol, Albert ^{[6
]}

Sureda, Anna ^{[5
]}

Escoda, Lourdes ^{[7
]}

Sarra, Josep ^{[7
]}

Garzo, Ana ^{[1
]}

Lloveras, Natalia ^{[1
]}

Gomez, Beatriz ^{[1
]}

Granada, Isabel ^{[6
]}

Gallardo, David ^{[1
]}

机构：

[1] Univ Girona, Josep Carreras Res Inst, Inst Catala Oncol,Hosp Dr Josep Trueta, Inst Invest Biomed Girona IDIBGI,Hematol Dept, Girona, Spain

[2] Hosp Canc Registry Unit, Catalan Inst Oncol, Girona, Spain

[3] Univ Girona, Res Grp Stat Econometr & Hlth GRECS, Girona, Spain

[4] Ctr CIBER Epidemiol & Publ Hlth CIBERESP, Girona, Spain

[5] Univ Barcelona, Inst Catala Oncol, Inst Invest Biomed Bellvitge IDIBELL, Clin Hematol Dept, Barcelona, Spain

[6] Hosp Badalona Germans Trias & Pujol, Josep Carreras Res Inst, Inst Catala Oncol, Hematol Dept, Barcelona, Spain

[7] Univ Rovira i Virgili URV, Hosp Joan XXIII, Inst Catala Oncol, Hematol Dept, Tarragona, Spain

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷

关键词：

CD200; polymorphisms; multiple myeloma; immune checkpoint; bone marrow microenvironment; immune disfunction; THERAPEUTIC TARGET; EXPRESSION; SUSCEPTIBILITY; GLYCOPROTEIN; IMMUNITY; DISEASE; GENES; RISK;

D O I：

10.3389/fimmu.2024.1252445

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events.

引用

页数：11

共 40 条

[1] A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039) [J].